Neurogenesis and Inflammation after Ischemic Stroke: What is Known and Where We Go from Here

Abstract

This review covers the pathogenesis of ischemic stroke and future directions regarding therapeutic options after injury. Ischemic stroke is a devastating disease process affecting millions of people worldwide every year. The mechanisms underlying the pathophysiology of stroke are not fully understood but there is increasing evidence demonstrating the contribution of inflammation to the drastic changes after cerebral ischemia. This inflammation not only immediately affects the infarcted tissue but also causes long-term damage in the ischemic penumbra. Furthermore, the interaction between inflammation and subsequent neurogenesis is not well understood but the close relationship between these two processes has garnered significant interest in the last decade or so. Current approved therapy for stroke involving pharmacological thrombolysis is limited in its efficacy and new treatment strategies need to be investigated. Research aimed at new therapies is largely about transplantation of neural stem cells and using endogenous progenitor cells to promote brain repair. By understanding the interaction between inflammation and neurogenesis, new potential therapies could be developed to further establish brain repair mechanisms.

Keywords

acute stroke brain ischemia inflammation neural stem cells regeneration and recovery

INTRODUCTION

Stroke is the fourth leading cause of death annually in the United States¹ and is the most common cause of permanent disability in adults worldwide.^2,3 Nearly 90% of all stroke victims experience an ischemic event caused by the sudden blockage of blood flow from a thrombus or embolism.^1,4 This percentage is even higher if one includes hemorrhagic stroke patients who may experience delayed ischemic events arising from arterial or arteriolar vasospasms associated with subarachnoid hemorrhage. Although the exact mechanism(s) responsible for the brain damage occurring after an ischemic insult is/are not fully understood, there is an increasing amount of evidence suggesting that post-ischemia inflammation is a significant contributing factor to the pathogenic process. Ischemia is accompanied by a rapid increase in inflammatory mediators causing irreversible damage to neurons in the ischemic core, with more long-term consequences ultimately appearing in the ischemic penumbra. However, those pathologies can be largely ameliorated via prompt restoration of blood flow. Clinically, this reperfusion can occur spontaneously or via the use of either pharmacological thrombolysis or endovascular thrombectomy. At the present time, the thrombolytic agent tissue plasminogen activator (tPA) constitutes the only FDA-approved therapy for acute ischemic stroke. However, tPA has several shortcomings including the potential risk of hemorrhagic transformation, therapeutic window limited to 3 hours from time of symptom onset, and limited efficacy, among others. Data obtained from the Get With The Guidelines-Stroke database shows that only 4% to 7% of all the acute ischemic stroke patients are treated with tPA,⁵ an observation that highlights the need for novel and effective therapeutic approaches.

The last decade or so has produced large amounts of evidence supporting the existence of neurogenesis in adult mammals. Mammalian brains contain neural stem cells (NSCs) that have the ability to self-renew, proliferate, and differentiate into multiple lineages.⁶ The participation of these cells in the process of adult neurogenesis has attracted interest among members of the research community, especially about their use as possible therapeutic options for brain repair. Both transplantation of NSCs and the utilization of endogenous progenitor cells appear to be plausible strategies for brain injury repair. Exploring the interactions between inflammation and neurogenesis has not been fully studied, and gaining a better understanding of the relationship between these two processes could help in the development of new and exciting therapeutic options for brain repair.

ISCHEMIC STROKE

Ischemic stroke causes damage as a result of primary and secondary insults mediated by ischemia and inflammation. Primary injury results from the initial ischemic period, which deprives the brain of oxygen and vital nutrients, such as glucose, critical for survival of central nervous system (CNS) cells. Neurons in the infarcted tissue die as a result of the initial injury whereas cells in the penumbra are affected by the rapid influx of immune cells, reactive oxygen species, and toxic inflammatory mediators.⁷ Current therapeutic options for ischemic stroke, and the less damaging transient ischemic attack, are aimed at dissolving the clot causing the blockage of blood flow and reestablishing perfusion of the infarcted area. Although these strategies are beneficial, reperfusion can also further the injury by increasing local inflammation and inducing chronic changes in axonal structure and function, which can increase neuronal damage.⁸

There are a number of strategies currently under investigation in the preclinical setting aimed at restoring brain function after ischemic insult. These strategies concentrate not on blood flow restoration but rather on inducing neuroprotection and salvaging brain function after the initial injury. Pharmacologic hypothermia, induced by the TRPV1 channel agonist dihydrocapsaicin, has been shown to be neuroprotective if given within 90 minutes of reperfusion after transient middle cerebral artery occlusion in mice.⁹ Furthermore, the pharmacologic agent, LJP-1586, which targets and inhibits leukocyte trafficking has been shown to confer neuroprotection after middle cerebral artery occlusion in a rat model of ischemic stroke.¹⁰ In addition, by preventing interactions of the receptor for advanced glycation endproducts with its ligands (e.g., high-mobility group box-1 and S100B), one can promote corresponding reductions in post-ischemic neuroinflammation and neuropathology.¹¹

NEUROINFLAMMATION

Inflammation in the Mammalian Brain

In the intact brain, trafficking of cellular and molecular components from the peripheral circulation is regulated by the blood–brain barrier (BBB). However, after brain injury, the tight junctions between endothelial cells of the BBB become permeable, allowing peripheral immune cells to infiltrate brain parenchyma. These cells, along with the proinflammatory cytokines they secrete, contribute to the inflammatory response that follows brain injury. Acute inflammation arises both from responses of resident immune cells, the microglia, as well as from infiltrating immune cells of the peripheral circulation.¹² Inflammation of the mammalian brain, however, is not only a response mechanism that follows CNS injury, such as from traumatic brain injury, spinal cord injury, and stroke. It is also often a large contributing factor to neurologic diseases such as Alzheimer's disease, amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson's disease.^13,14 Chronic inflammation and the release of proinflammatory molecules from immune cells have also been implicated as causative factors of neurodegeneration and CNS disorders.^14,15 The term ‘inflammation,’ and subsequently the ‘inflammatory response,’ seek to combine many different processes and pathways into one unified theme when, in fact, they are distinct pathways that have different downstream consequences. Therefore, it is imperative to keep in mind that, although all of the aforementioned pathologies and pathologic states have an inflammation-related component to them, the specific inflammatory response could be, and most likely is, very different among the various diseases and injuries.

Susceptibility to stroke and subsequent prognosis are highly influenced by peripheral inflammatory cells. Numerous inflammatory cells, including neutrophils, macrophages, and T cells, are recruited to sites of ischemic injury.¹⁶ The mechanism by which these cells decrease neurogenesis after ischemic injury, and the way in which they affect NSCs, remains largely unknown. Post-ischemic inflammation is characterized by microglia activation followed by infiltration of circulating inflammatory cells.^16–20 Acutely, reactive oxygen species and inflammatory mediators cause endothelial cell and leukocyte expression of adhesion molecules, promoting the adhesion and migration of circulating leukocytes that leads to a rapid inflammatory state at the site of injury. These leukocytes further release inflammatory cytokines that lead to tissue damage in the injury site and the ischemic penumbra (Figure 1).

Figure 1.

Inflammatory cascade leading to secondary brain inflammation and cell death after ischemic injury. Cerebral ischemia alone leads to both an initial cell necrosis and generation of reactive oxygen species (ROS) and proinflammatory molecules like interleukin-1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) from injured neurons as well as inducing blood–brain barrier (BBB) dysfunction with loosening of cell-to-cell tight junctions between endothelial cells and upregulation of endothelial cell expression of various cell adhesion molecules (e.g., vascular cell adhesion molecules (VCAM), intracellular adhesions molecule-1 (ICAM-1)). This increase causes adherence, migration, and extravasation of circulating leukocytes into the brain parenchyma. When in the brain, leukocytes and activated microglia generate a variety of proinflammatory molecules like inducible nitric oxide synthase (iNOS), matrix metalloproteinases (MMPs), IL-1β and TNF-α, and continue to generate ROS. These events lead to secondary brain injury, increased inflammation, and ultimately cell death. ECM, extracellular matrix; NO, nitric oxide.

Like any ischemia–reperfusion injury, a large portion of the damage is due to the inflammatory cascade that follows reperfusion. This response results in an increase in toxic inflammatory mediators including, but not limited to, interleukin (IL)-1β, IL-6, IL-8, and tumor necrosis factor-alpha (TNF-α).²¹ An increase in these molecules is sufficient to induce neuronal apoptosis within the infarcted tissue, ultimately causing irreversible brain damage. In addition to the presence of these classic inflammatory molecules, nitric oxide is dramatically increased after ischemia. While nitric oxide is neuroprotective at low levels,²² high levels, such as those observed after ischemia–reperfusion injury, have been shown to be pathologic as well as proapoptotic by further increasing reactive oxygen species production.²² These mechanisms are universal to all ischemia–reperfusion-type injuries and are not unique to cerebral ischemia. However, because neurons are especially sensitive to ischemia, it is critical to understand the neural response to inflammation after ischemia–reperfusion to begin contemplating therapies for such injuries.

Peripheral Versus Resident Immune Response after Ischemic Injury Under normal physiologic conditions, trafficking of peripheral immune cells into the brain is restricted.²³ This status is maintained by the BBB. Under such conditions, immune surveillance in the CNS is performed by resident microglia. When the BBB becomes dysfunctional, as occurs after injury, circulating immune cells can gain direct access to the brain. The relative contributions to the inflammatory response from peripheral immune cells and resident immune cells after injury, though, need to be further elucidated.

Acutely (4 to 24 hours) after ischemic injury, circulating immune cells begin to adhere to, and migrate along, the damaged endothelium lining the cerebral vasculature and start to infiltrate into brain parenchyma owing to the breakdown of the BBB.²⁴ Macrophages, which reside in the perivascular space in the glia limitans, are a large driving force behind infiltration of peripheral immune cells into the brain parenchyma.²⁵ Macrophages exist in multiple states that are phenotypically and functionally distinct. M1-type macrophages are proinflammatory and secrete numerous inflammatory mediators such as TNF-α, IL-1β, IL-8, IL-12, and reactive oxygen species.^26,27 M2-type macrophages are antiinflammatory in nature and secrete antiinflammatory cytokines like IL-10, TGF-β, and have increased expression of the enzyme arginase.^26,27 Owing to the secretion of factors by macrophages, namely IL-8, and by binding to cell adhesion molecules on endothelial cells, neutrophils infiltrate the brain and release their secretory granules, which include various proinflammatory molecules such as nitric oxide, myeloperoxidase, multiple matrix metalloproteinases, and elastase.^26,28 Secretion of these factors by both macrophages and neutrophils initiates the acute phase of the innate immune response.

After macrophage and neutrophil infiltration, lymphocytes begin to infiltrate the brain as well.²⁴ Under normal conditions, naïve T cells are not capable of migrating through the BBB to enter the brain. However, after injury, activated CD4⁺ and CD8⁺ T cells can enter the brain in an antigen- and major histocompatibility complex-independent fashion.^29,30 In addition, there is evidence showing the presence of CNS-specific T cells located within the choroid plexus that promotes leukocyte trafficking into the CNS after injury.^31,32 Approximately 15% of these choroid plexus T cells are CD4⁺ T_H1 cells, which secrete interferon-γ. Interferon-gamma is critical for further recruitment of immune cells.^31,32 These T_H1 cells further stimulate cytotoxic CD8⁺ T cells, which secrete the membrane-permeabilizing molecule perforin and induce apoptosis via granzyme-induced caspase activation or via activation of the Fas ligand pathway. In addition to T_H1 cells, T_H2 cells secrete numerous interleukins (IL-4, 5, 9, 10, and 13) that are important for activation and recruitment of cells, namely B cells, involved in the humoral immune response. In the case of ischemic injury, the humoral immune response is less important; however, in infectious processes and degenerative diseases like multiple sclerosis, this response is crucial for development of pathology. In addition to helper T cells, a small population of γδ T cells has been implicated in both cytotoxicity and protective immune modulation. It is unclear, however, what their role is in neuroinflammation.²⁶

While the peripheral immune response is an extremely important factor in neuroinflammation, the response of activated microglia is of equal, if not more, importance. Resting microglia are the resident immune cells of the brain and their job is to actively survey the brain. Like peripheral antigen-presenting cells, microglia are continuously extending and retracting their processes looking for any signs of damage. Similar to macrophages, microglia also exist in two different states, the M1 and M2 phenotypes.³³ On activation, as occurs in ischemic injury, microglia take on the M1 phenotype and secrete various proinflammatory molecules including IL-1β, TNF-α, and reactive oxygen species. In addition, microglia can take on the M2 phenotype and secrete the antiinflammatory molecules IL-10 and TGF-β, which govern the resolution of post-ischemic inflammation as well as growth factors implicated in brain repair (IGF-1 and glial cell line-derived neurotrophic factor).^26,32 Table 1 summarizes many of the molecules that are known to be released during brain injury and their functions associated with the inflammatory cascade. This table is not exhaustive but highlights what are thought to be the most important signaling molecules associated with neuroinflammation.

Table 1.

Signaling molecules associated with the inflammatory cascade

Released factor	Function	Produced by	Role in stroke	Time to peak concentration	Species—method of stroke
Proinflammatory
TNF-α	Upregulation of caspases Upregulation of leukocyte adhesion molecule expression Increases endothelial cell dysfunction	Neurons, M1-type microglia, M1-type macrophages	Increases¹¹³ or decreases¹¹⁴ infarct volume	3–24 hours^114–117	Mouse—pMCAO^114,115 Mouse—tMCAO¹¹⁶ Rat—tMCAO¹¹⁷
IL-1α/β	Apoptosis	M1-type macrophages, microglia, endothelial cells	Increases infarct volume¹¹⁸	6–24 hours^115,117,119	Mouse—tMCAO¹¹⁵ Rat—tMCAO^117,119
IL-6	Pyrogen	Macrophages, endothelial cells	Neuroprotective^120–122	6–18 hours^117,119	Rat—tMCAO^117,119
IL-8	Neutrophil chemoattractant	Macrophages, endothelial cells	Increases infarct volume¹²³	1–3 days¹²⁴	Peripheral blood from human stroke patients¹²⁴
IL-12	Promote T_H1 phenotype	Macrophages, T_H1 cells	Increases infarct volume¹²⁵	Unknown
IFN-γ	Macrophage activation	NK cells, T cells	Increases infarct volume¹²⁶	10–14 days¹²⁷	Rat—transient 4VO¹²⁷
iNOS	Production of NO	Astrocytes, microglia, leukocytes, endothelial cells	Increases infarct volume¹²⁸	12 hours¹²⁹	Rat—tMCAO¹²⁹
MMPs	Degradation of ECM proteins	Astrocytes, leukocytes	Increases infarct volume^130,131	12–24 hours¹³²	Blood plasma from human MCA stroke patients¹³²
Elastase	Degradation of basal lamina and ECM proteins Recruitment of leukocytes	Neutrophils, macrophages	Increases infarct volume¹³³	12 hours¹³⁴	Mouse—tMCAO¹³⁴
Antiinflammatory
IL-10	Blocks conversion to T_H1 phenotypeInhibits synthesis of IFN-γ, IL-2, IL-3, TNF-α	Microglia, macrophages, T_reg cells, endothelial cells	Decreases infarct volume^135–137	24 hours¹²⁷	Rat—transient 4VO¹²⁷
Arginase	Decreases production of NO	M2-type macrophages, microglia	Unknown	8–15 days¹³⁸	Rat—photothrombotic cortical occlusion¹³⁸
TGF-β	Inhibition of lymphocyte and monocyte-derived phagocyte activation	Microglia, M2-type macrophages	Decreases infarct volume^139–141	2–4 days^142,143	Rat—4VO¹⁴²Rat—pMCAO¹⁴³
Others
ROS	Oxidation of cell signaling molecules	Neurons, microglia, astrocytes, leukocytes	Increased production after stroke^144,145Early ROS burst increases infarct volume¹⁴⁶	10 minutes–72 hours^146,147	Rat—2VO¹⁴⁷Mouse—tMCAO¹⁴⁶
MPO	Generation of ROS	Neutrophils, macrophages	Decreases infarct volume¹⁴⁸	3 days¹⁴⁹	Mouse—tMCAO¹⁴⁹

ECM, extracellular matrix; IFN-γ, interferon-gamma; IL, interleukin; iNOS, inducible nitric oxide synthase; MMP, matrix metalloproteinase; MPO, myeloperoxidase; pMCAO, permanent middle cerebral artery occlusion; ROS, reactive oxygen species; TGF-β, transforming growth factor-β tMCAO, transient middle cerebral artery occlusion; TNF-α, tumor necrosis factor-α 2VO, 2-vessel occlusion (bilateral carotid artery occlusion); 4VO, 4-vessel occlusion (bilateral carotid artery and bilateral vertebral artery occlusion).

Neuroinflammation after ischemic stroke is, for the most part, a self-limiting event. However, unlike systemic inflammation that subsides due largely in part to exhaustion of inflammatory mediators, resolution of inflammation in the brain seems to be an active process in which inflammatory mediators are suppressed by regulatory mechanisms.²⁶ Among these suppressor molecules are arachidonic acid derivatives such as lipoxins, resolvins, and protectins.³⁴ Furthermore, resolution of inflammation in the brain, similar to systemic inflammation, involves clearing of dead and dying cells primarily via the phagocytic activity of activated microglia with help from infiltrating macrophages^35,36 as well as production of antiinflammatory, proregenerative signaling molecules like IL-10 and TGF-β, which both suppress inflammation and exert neuroprotective effects on the surviving cells.²⁶ In the chronic phase of stroke, there is little contribution from either resident or peripheral immune cells; however, there is still an increase in the number of microglia that help in brain repair via clearing of dead and dying cells.^11,35,36

Current research aimed at the inflammatory state after ischemia is targeted at reducing infarct size after ischemia.^16–20 While this approach is important, it does not address a crucial aspect of repair: the neural stem cell. Neural stem cell numbers increase after ischemic stroke; however, they rapidly die³⁷ thereby preventing successful brain repair. By understanding how inflammation increases the susceptibility toward premature NSC death, we can better design therapies to promote brain repair.

NEUROGENESIS IN THE ADULT BRAIN

Traditionally, neurogenesis was thought to only occur during embryonic and perinatal development;³⁸ however, over the last decades, it has become clear that neurogenesis occurs throughout adulthood in distinct regions of the brain. These regions consist of the subventricular zone (SVZ), located adjacent to the lateral ventricle, and the subgranular layer (SGL) of the dentate gyrus (DG) in the hippocampus. Furthermore, these two regions of the brain maintain distinct populations of NSCs that exhibit multipotency and greater plasticity compared with other cellular components of the central nervous system.⁶ The NSCs located in the SVZ, referred to as radial glia-like B cells, are quiescent, glial fibrillary acidic protein (GFAP) positive, and have characteristics in common with astrocytes.^6,39 These type B cells give rise to the so-called transit-amplifying type C cells, which are GFAP negative. From there, type C neural progenitor cells (NPCs) give rise to doublecortin (DCX)-expressing neuroblasts. In rodents and nonhuman primates, these neuroblasts travel through the rostral migratory stream (RMS) to the olfactory bulb where they ultimately become periglomerular neurons or granule cells (Figure 2).^6,40 However, while there is a comparable SVZ region in the human brain, there exists a unique hypocellular layer that lacks cellular bodies. This region is thought to be the site for the regulation of neuronal function, metabolic homeostasis, and/or NSC proliferation and differentiation.⁴¹ Furthermore, the existence of an RMS or any pathway leading to the olfactory bulb is controversial with previous studies lacking demonstration of a similar RMS track in humans.^40,42 However, more recent studies^43,44 describe the presence of NSCs in the human striatum⁴³ and also the presence of an RMS in humans with neuroblast migration to the olfactory bulb (Figure 3).^44,45 These studies illustrate the ongoing discussion in the scientific community about the presence or absence of an RMS in humans and demonstrate the need for further research to fully elucidate the extent of adult human neurogenesis.

Figure 2.

Adult neurogenesis in rodents. Coronal sections of the rodent show the neurogenic environments of the adult brain: the subventricular zone (SVZ; left panel) and the subgranular layer (SGL; right panel). The SVZ contains type B neural stem cells (NSCs), which give rise to transit-amplifying type C cells followed by type A migrating neuroblasts. These cells migrate along the rostral migratory stream (RMS) toward the olfactory bulb before terminal differentiation. The SGL contains type I NSCs, which are similar to the type B cells in the SVZ. Type I NSCs give rise to type II NPCs (or intermediate progenitors; IP), which can be further classified as type IIa and type IIb. These type IIb cells are early committed neuronal progenitor cells, which give rise to type III neuroblasts, which migrate into the granular cell layer where they exit the cell cycle and become mature neurons. All cell types described here can be identified based on a unique set of molecular and morphologic markers, as described in the cell population column. GCL, granular cell layer; GFAP, glial fibrillary acidic protein.

Figure 3.

Adult neurogenesis in humans. Coronal sections of the human brain show the neurogenic environments of the adult brain: the subventricular zone (SVZ; left panel) and the dentate gyrus (DG) of the hippocampus (right panel). Cell types unique to these regions as well as the fate of these cells are listed. Cell types described here can be identified based on a unique set of molecular and morphologic markers, as noted in the cell population column. GCL, granular cell layer; LV, lateral ventricle; SGL, subgranular layer.

Neural stem cells in the DG give rise to new neurons which reside within the granular cell layer (GCL). In both rodents and humans, two distinct subpopulations can be identified in the DG that are unique in their morphologies and molecular marker expression profiles. Similar to the type B cells of the SVZ, type I cells express GFAP and have a similar radial glia-like morphology. Type II cells are more similar to the type C cells of the SVZ and are also GFAP negative. Type II cells can be further subdivided into two subpopulations: (1) type IIa cells, which express Mash1 and continue to express the NSC marker Sox2, and (2) type IIb cells, which are early committed NPCs, which express the transcription factors Prox1, NeuroD1, and DCX. Like in the SVZ, NSCs in the DG proceed through similar levels of differentiation from type I/II NSCs to NPCs to DCX-positive neuroblasts and ultimately into new, mature neurons in the GCL.⁴⁶ These newly formed neurons project axons into the CA3 region of the hippocampus and dendrites into the molecular layer of the DG, where they form synapses with entorhinal terminals much like neurons formed during embryogenesis.^6,47 The rate at which this happens in vivo has been found to be comparable between adult mice and middle-aged humans, with a calculated annual turnover rate of 1.75 percent, suggesting that there is a sufficient amount of neurogenesis (~700 new neurons per hippocampus per day) occurring in humans that could significantly contribute to functional repair.⁴² The growing evidence supporting the occurrence of neurogenesis in humans, particularly in areas highly sensitive to oxygen deprivation such as the hippocampus, suggests its potential role in neural repair after stroke. Additional studies are needed to understand this complex process, the mechanisms that affect it, and how it can be manipulated for the treatment of neurologic diseases.

Interaction between Inflammation and Neurogenesis

Thoughtful research has demonstrated the active role of neuroinflammation in both secondary brain injury and neurorepair after stroke. The effect of the post-ischemic immune response on neurogenesis is not well understood. However, studies done in different models of disease demonstrated that an active cross talk exists between inflammation and neurogenesis. Invertebrate models of brain injury and inflammation showed that inflammation is both sufficient and necessary to increase endogenous neurogenesis after injury.⁴⁸ Data obtained in vertebrate models of chronic neuroinflammation induced by stereotaxically injected lipopolysaccharide into the DG, for example, demonstrated the functional integration of new, adult born, highly plastic hippocampal neurons.⁴⁹ Also, the presence of chronic inflammation induced by electrical induction of status epilepticus was linked to a sevenfold increase in the number of mature neurons in the dentate GCL formed during the first 2 weeks after seizure induction with the majority of these newborn cells replacing dead granule cells. Significantly, 6 months after seizure activity, there was evidence of continued neuron formation in the hilus of the DG supporting the long-term effect of inflammation on neurogenesis.⁵⁰ These reports are promising for utilization of endogenous neurogenesis as a repair mechanism after brain injury. However, the interplay of inflammation and neurogenesis is complex and there is substantial evidence obtained in vertebrate models of brain injury that show that inflammation impairs not only basal neurogenesis levels but also attenuates the increased neurogenesis seen after injury via increased activated ED1⁺ microglia⁵¹ and via secretion of numerous proinflammatory cytokines including IL-6, TNF-α, and interferon-γ.^44,51–55 As an illustration, mice continuously infused with lipopolysaccharide have an 85% reduction in new neurons with no corresponding effect on already mature neurons and this phenomenon can be alleviated via antiinflammatory treatment with minocycline.⁵¹ Mechanistically, hippocampal neurogenesis can be downregulated by proinflammatory cytokines, such as IL-6^44,52 and nitric oxide⁵⁶ secreted by immune cells.^44,52,56 Conversely, NPCs have been shown to promote neuroprotection via immunomodulation suggesting an innate and mutual interaction between NSCs and the immune system.⁵⁷

Both pro- and antiinflammatory cytokines can influence the proliferation and migration of neural progenitors.^58,59 The link between the immune response that occurs after ischemic stroke, neurogenesis, and subsequent functional recovery has not been well established; however, hypotheses regarding both the beneficial⁶⁰ and detrimental^61,62 effects of inflammation have been proposed. Some of the beneficial effects have been attributed to the interaction of T cells with microglia, which stimulates proliferation of SGL and SVZ progenitor cells⁶⁰ and directs both NPC migration and differentiation in vitro and in vivo.⁶³ Furthermore, hippocampal neurogenesis induced via enriched environment demonstrates an increase in CNS T-cell recruitment and activation of microglia in wild-type mice with impaired neurogenesis in immune-deficient, SCID and nude mice.⁶⁰ Some of the detrimental effects have been proposed to be caused by progenitor cell suppression via TNF-α secretion by activated microglia.^61,62 Furthermore, lipopolysaccharide-activated microglia have been shown to compromise survival of newly formed neurons after brain injury.^51,64 In addition, in contrast to acute activation of microglia, chronic microglia activation seems to confer a neuroprotective effect supporting NSC survival. Newly born neurons that do not die after acute status epilepticus-induced microglia activation survive for at least 6 months after injury in the presence of chronically activated microglia.⁶⁵ Further in vivo studies have demonstrated unique proneurogenic phenotypes of microglia in the SVZ after stroke whereby activated microglia not only exhibited a ramified morphology, typical for resting microglia, but have increased production of IGF-1, a diffusible neurotrophic factor important for NPC proliferation.^11,50 in vitro studies have also supported a beneficial role of microglia showing that NSCs co-cultured with microglia or grown in microglia-conditioned media have increased formation of neuroblasts, which is otherwise lost after long-term culture.^66,67 In contrast, NSCs co-cultured with increasing ratios of microglia in an acute setting demonstrated a dose-dependent reduction in NPC number.⁶⁸ It is clear that there exists an intimate relationship between neurogenesis and the inflammatory response that has a crucial role in the response after brain injury. The dual roles that microglia have after stroke is becoming increasingly more apparent, and it would seem that the microglia response has both beneficial and negative consequences for neurogenesis.⁶⁹ By further understanding this interaction and the relationship between these two processes, our understanding of CNS injury and repair can be further advanced.

Effect of Ischemia on Neurogenesis

There are increasing amounts of evidence suggesting that ischemic injury drastically increases neurogenesis in the rodent SVZ and SGL^70–73 as well as in the primate SGL.^74,75 Furthermore, studies in mice^76,77 and rats^78–82 demonstrate an increase in NPC proliferation in the DG peaking around 7 days after ischemic injury.^70,77,80 However, the increased number of NSCs quickly returns to baseline with most of the NSCs dying shortly after proliferation. In fact, the number of NPCs that survive and become mature neurons are approximately equal in number in animals undergoing ischemia compared with animals without injury. The cells that do survive, however, migrate from the SGL into the GCL, have increasing dendritic length, and begin to both lose expression of immature neuronal markers and gain expression of mature neuronal markers with increasing time after ischemia after a similar time course to normal neuronal maturation.⁸³ Despite the increase in NPC numbers after an ischemic injury, these cells prematurely die without the ability to repair dead tissue. The mechanisms by which these NPCs die early are as yet undetermined.

Similar to the SGL, NPCs in the SVZ have a short-lived proliferation again peaking around 7 days after ischemia.^70,84 Also like the cells in the SGL, those NPCs that do survive migrate out of the SVZ into the striatum and neocortex and mature into 15 functional neurons.^73,85–89 In addition, it has been demonstrated that transient angiogenesis after stroke allows neuroblasts to migrate along these newly formed blood vessels aiding in their migration out of the SVZ.⁸⁹ While some of these newly generated neurons survive up to 5 weeks after ischemia, the majority seem to die with only ~0.2% of the cells surviving.⁷³ Furthermore, these surviving cells have been shown to be spiny neostriatal projection neurons^73,85 and small, calretinin⁺ interneurons.⁹⁰ Despite these promising data demonstrating functional maturation of NPCs in both the SVZ and SGL after ischemic injury, much work still needs to be done to determine why the majority of these cells die, why the initial NPC proliferation fails to promote brain repair, and how neurogenesis can be manipulated for the support of functional recovery.

PROSPECTIVE THERAPIES AFTER ISCHEMIC STROKE

Over the last decade, significant advances have been made in our understanding of the pathogenesis of brain injury from stroke. The knowledge gained, however, failed to translate into novel treatment strategies. Our current armamentarium to treat cerebral ischemia relies mainly on the use of pharmacological thrombolytics (tPA) in acute cases and antithrombotic therapy along with correction of the modifiable vascular risk factors for recurrent stroke prevention. The time window for initiating the treatment with tPA is limited to 3 hours after stroke symptom onset. The short therapeutic window, stroke severity, concern of the occurrence of major or fatal hemorrhage, severe hypertension, and other variables greatly limit the number of patients that can benefit from this treatment. The development and implementation of hospital-based protocols with the goal of facilitating the identification of ischemic stroke patients and the early treatment with tPA has increased the use of thrombolytics from 4% in the period 2003–2005 to 7% in 2010–2011 (P < 0.001). These statistics and the known negative consequences of stroke highlight the desperate need for new safe and effective treatments for this condition. Because patients are often unaware of initial stroke symptoms, many do not seek care until well after the 3 h window of tPA has passed. Thus, identifying new strategies that can be used beyond the current time window and regulate post-ischemia inflammation or enhance neurorepair are likely to revolutionize contemporary stroke care.

Antiinflammatory Treatment Strategies

As discussed previously, a large effector of stroke outcome is the post-ischemia inflammatory environment that exists. Therefore, large efforts are underway to target these inflammatory pathways in an attempt to reduce their effect on the brain after the initial ischemic injury. Various research studies as well as clinical trials have been conducted to examine the effect of various antiinflammatory treatments after ischemic stroke (Table 2). While two of these studies report better outcomes with their antiinflammatory treatment,^91,92 the remaining studies report worse outcomes,^93,94 no difference between treatment and placebo,^95–98 or were simply safety studies^99–101 with all of them failing to make it beyond clinical phase trials. Importantly, some of these studies were underpowered to detect a meaningful clinical effect. However, the dual effect of inflammation on stroke outcome and particularly on neurogenesis highlights that antiinflammatory strategies might be a difficult avenue to pursue in ischemic stroke treatment. Further studies, however, need to be conducted to hone in on more specific targets in the inflammatory cascade that can hopefully be effective targets for future therapeutic trials. One such target is vascular adhesion protein-1, which is expressed by endothelial cells and aides in neutrophil transmigration from the vasculature into the brain parenchyma. The pharmacologic agent LJP-1586, and its predecessor LJP-1207, are highly selective vascular adhesion protein-1 inhibitors and prevent neutrophil transmigration into the brain parenchyma. Furthermore, when these drugs are given to rodents subjected to transient forebrain ischemia¹⁰² or transient middle cerebral artery occlusion¹⁰ 6 to 12 hours after reperfusion, there is a profound antiinflammatory action, which is linked to neuroprotection.^10,102 These studies, and others currently in preclinical development may identify clinical targets for antiinflammatory therapeutic options.

Table 2.

Clinical studies utilizing antiinflammatory agents in acute ischemic stroke

Antiinflammatory agent	Mechanism of action	Outcome	Reference
Dexamethasone	Immunosuppressant	No difference from placebo	98
Recombinant IL-1RA	IL-1 receptor antagonist	Safe No SAE	99
Enlimomab	Anti-ICAM-1 monoclonal antibody	Worse progression	93
Tirilazad	Lipid peroxidation inhibitor	Worse progression	94
UK-279,276	Neutrophil inhibitory factor	No difference from placeboNo SAEStopped for futility	95
Cerovive (NXY-059)	Nitrone-based free radical trapping agent	Safe No SAE	96,100
Acetaminophen	Anti-pyretic effect	Results not reported	150
Minocycline	Antiinflammatory	Significant improvement over placebo	91
Ginsenoside	Ca²⁺ channel antagonist	No difference from placebo	97
Edaravone (MCI-186)	Free radical scavenger	Significant improvement over placebo	92
ONO-2506 (arundic acid)	Astrocyte modulator	Safe No SAE	101

ICAM, intracellular adhesions molecule; SAE, serious adverse events. Adapted from Lakhan, et al.⁴

However, while these studies offer promising avenues for future research, the fact that blocking post-ischemia inflammation could also eliminate any beneficial effects of inflammation cannot be overlooked. Although the consensus thus far that inflammation is largely detrimental to neurogenesis after stroke there is evidence, as discussed above, showing that chronic neuroinflammation supports maturation of highly plastic hippocampal NSCs.^49,50 Therefore, investigators must weigh the advantages and disadvantages when considering these types of treatment approaches, as they could potentially inhibit potent proregenerative effects.

Regenerative Strategies

Current therapies involving regenerative strategies have mostly involved two separate ideas: (1) the ability to repopulate infarcted tissue via transplantation of stem cells and (2) utilizing endogenous progenitor cells to repopulate the damaged brain. Transplantation of stem cells has been attempted in rodent models of disease^103–105 with some degree of success, showing benefit to the animals receiving stem cell transplantation. In both rodents and primates with damage to the hippocampus, functional recovery was seen after transplantation of both fetal and immortalized neuroepithelial stem cells.¹⁰³ In addition, when compared with young animals, aged animals (which naturally experience decreased endogenous neurogenesis) demonstrated increased performance on hippocampus-based memory tasks after transplantation of immortalized neuroepithelial stem cells.¹⁰⁴ Furthermore, human NSCs injected into aged rat brains successfully integrated into brain parenchyma and increased performance on hippocampus-based memory tasks.¹⁰⁵ Stem cell transplantation seems to be beneficial; however, getting stem cells to engraft with a high degree of efficiency and to differentiate into mature cells is highly variable. Furthermore, the translation of these studies in animal models to humans poses significant technical hurdles that would make the use of cell transplantation difficult in clinical practice. Consequently, utilizing endogenous neurogenesis mechanisms provides an alternative approach to regenerative therapies after ischemic injury.

Not only has transplantation of stem cells been shown to be directly beneficial to the injured brain, but it has also been shown to stimulate endogenous neurogenesis.¹⁰⁶ Endogenous neurogenesis, though, is not a one-step process. It is a series of events involving the proliferation of NSCs/NPCs, migration of these cells to the damaged area, survival of these cells, differentiation of progenitor cells into different lineages of neural cells, and functional integration of these mature cells. Therefore, therapies aimed at each of these steps could prove beneficial in successful brain repair after ischemic stroke. As discussed earlier, proliferation of NSCs does not seem to be impaired after stroke. Rather, it is the survival of these progenitor cells that seems to be hindered with up to 80% of newborn neurons dying within 2 weeks after their birth.⁶⁹ It would therefore seem that therapies aimed at increasing the survival of NSCs and NPCs would be the most advantageous. These strategies, though, are not without complication. The existence of large numbers of NSCs is not seen in humans to the same extent as in rodents.^70,107 Consequently, manipulation of endogenous NSCs alone may not be sufficient to adequately repopulate damaged brain tissue.

Furthermore, the pathologic environment created after ischemic stroke pose numerous hurdles for newborn neurons that makes the utilization of endogenous repair mechanisms difficult. For instance, aged and injured brains have reduced neurogenic signaling making it even more difficult to direct the migration and differentiation of endogenous NSCs needed to repair infracted tissue.^6,108 In addition, unlike other areas of the body, the brain is unique in its response to hypoxic cell death in that it ultimately leads to gliotic scar formation and liquefactive necrosis, which will negatively impact all aspects of endogenous repair. Not only will NPCs and neuroblasts be unable to migrate but any surviving newborn neurons will have difficulty integrating into existing circuits and forming functional synaptic connections. Because of these issues, successful recruitment and differentiation of NSCs into cortical and subcortical structures may be difficult to attain, making the use of endogenous progenitor cells an unlikely source of independent brain repair.

Despite these obstacles, newborn neurons have several advantages compared with mature cells that can help overcome these barriers. The most obvious of these advantages is that, unlike the postmitotic mature neurons, NSCs and NPCs can undergo asymmetric cell division and not only produce mature daughter neurons but can maintain the stem and progenitor pools allowing for continued brain repair. In addition, it has been shown that young, newborn neurons in the GCL of the DG are more active than old granule cells and that the young cells are necessary for enhanced pattern separation.¹⁰⁹ Furthermore, immature and newborn neurons are more excitable than mature cells. Consequently, they fire more action potentials in a given time than their mature counterparts.^110–112 Thus, overall circuit excitation will be increased, which could help ameliorate some of the loss of excitation after cell death after ischemia. Therefore, in combination with other strategies such as stem cell transplantation, the use of endogenous neurogenesis mechanisms could prove to be extremely beneficial for brain repair.

CONCLUSIONS

Ischemic stroke is a devastating disease that affects millions of people every year. The basic mechanisms leading to the full extent of damage are still not fully understood. Furthermore, strategies to repair the brain after ischemic injury have left hopes for successful treatment largely unfulfilled. It is becoming more and more evident that inflammation has a substantial role in the insult obtained after ischemia and that neurogenesis is in some way affected by this inflammation. How these two processes are related is still highly debated, but it seems that their interaction is critical in understanding at least part of the mechanism behind the ischemic injury. By elucidating the relationship between inflammation and neurogenesis after stroke, it is possible that better, more efficient therapies could be developed to aid in brain repair after ischemic injury. However, only by understanding this relationship can we hope to successfully implement therapies that may be developed in the future.

Footnotes

The authors declare no conflict of interest.

References

Towfighi

Saver

. Stroke declines from third to fourth leading cause of death in the United States: historical perspective and challenges ahead. Stroke 2011; 42: 2351–2355.

Donnan

Fisher

Macleod

Davis

. Stroke. Lancet 2008; 371: 1612–1623.

Mozaffarian

Roger

Benjamin

Berry

Blaha

. Heart disease and stroke statistics–2014 update: a report from the American Heart Association. Circulation 2014; 129: e28–e292.

Lakhan

Kirchgessner

Hofer

. Inflammatory mechanisms in ischemic stroke: therapeutic approaches. J Transl Med 2009; 7: 97.

Schwamm

Ali

Reeves

Smith

Saver

Messe

. Temporal trends in patient characteristics and treatment with intravenous thrombolysis among acute ischemic stroke patients at Get With The Guidelines-Stroke hospitals. Circ Cardiovasc Qual Outcomes 2013; 6: 543–549.

Lazarov

Mattson

Peterson

Pimplikar

van Praag

. When neurogenesis encounters aging and disease. Trends Neurosci 2010; 33: 569–579.

Borgens

Liu-Snyder

. Understanding secondary injury. Q Rev Biol 2012; 87: 89–127.

Zhang

Gao

Luo

Chen

Gao

. Transient focal cerebral ischemia/reperfusion induces early and chronic axonal changes in rats: its importance for the risk of Alzheimer's disease. PloS One 2012; 7: e33722.

Cao

Balasubramanian

Marrelli

. Pharmacologically induced hypothermia via TRPV1 channel agonism provides neuroprotection following ischemic stroke when initiated 90 minutes after reperfusion. Am J Physiol Regul Integr Comp Physiol 2014; 306: R149–R156.

10.

Watcharotayangul

Mao

Vetri

Baughman

Paisansathan

. Post-ischemic vascular adhesion protein-1 inhibition provides neuroprotection in a rat temporary middle cerebral artery occlusion model. J Neurochem 2012; 123(Suppl 2): 116–124.

11.

Thored

Heldmann

Gomes-Leal

Gisler

Darsalia

Taneera

. Long-term accumulation of microglia with proneurogenic phenotype concomitant with persistent neurogenesis in adult subventricular zone after stroke. Glia 2009; 57: 835–849.

12.

Aktas

Ullrich

Infante-Duarte

Nitsch

Zipp

. Neuronal damage in brain inflammation. Arch Neurol 2007; 64: 185–189.

13.

Minghetti

. Role of inflammation in neurodegenerative diseases. Curr Opin Neurol 2005; 18: 315–321.

14.

Eikelenboom

Veerhuis

Scheper

Rozemuller

van Gool

Hoozemans

. The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 2006; 113: 1685–1695.

15.

del Zoppo

. Acute anti-inflammatory approaches to ischemic stroke. Ann N Y Acad Sci 2010; 1207: 143–148.

16.

Jin

Yang

. Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leuk Biol 2010; 87: 779–789.

17.

Amantea

Nappi

Bernardi

Bagetta

Corasaniti

. Post-ischemic brain damage: pathophysiology and role of inflammatory mediators. FEBS J 2009; 276: 13–26.

18.

Kriz

. Inflammation in ischemic brain injury: timing is important. Crit Rev Neurobiol 2006; 18: 145–157.

19.

Schilling

Besselmann

Leonhard

Mueller

Ringelstein

Kiefer

. Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2003; 183: 25–33.

20.

Tanaka

Komine-Kobayashi

Mochizuki

Yamada

Furuya

Migita

. Migration of enhanced green fluorescent protein expressing bone marrowderived microglia/macrophage into the mouse brain following permanent focal ischemia. Neuroscience 2003; 117: 531–539.

21.

Janardhan

Qureshi

. Mechanisms of ischemic brain injury. Curr Cardiol Rep 2004; 6: 117–123.

22.

Fiscus

Yuen

Chan

Kwong

Chew

. Nitric oxide and cyclic GMP as pro- and anti-apoptotic agents. J Cardiac Surg 2002; 17: 336–339.

23.

Rezai-Zadeh

Gate

Town

. CNS infiltration of peripheral immune cells: D-Day for neurodegenerative disease? J Neuroimmune Pharmacol 2009; 4: 462–475.

24.

Stevens

Bao

Hollis

Lessov

Clark

Stenzel-Poore

. The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res 2002; 932: 110–119.

25.

Konsman

Drukarch

Van Dam

. (Peri)vascular production and action of pro-inflammatory cytokines in brain pathology. Clin Sci 2007; 112: 1–25.

26.

Iadecola

Anrather

. The immunology of stroke: from mechanisms to translation. Nat Med 2011; 17: 796–808.

27.

Mantovani

Sica

Locati

. Macrophage polarization comes of age. Immunity 2005; 23: 344–346.

28.

Yilmaz

Granger

. Leukocyte recruitment and ischemic brain injury. Neuromol Med 2010; 12: 193–204.

29.

Stenzel

Alber

. Regulation of the inflammatory response in brain. In: Lajtha

Galoyan

Besedovsky

(eds) Handbook of Neurochemistry and Molecular Neurobiology. Springer: US, 2008, pp 235–262.

30.

Hickey

Hsu

Kimura

. T-lymphocyte entry into the central nervous system. J Neurosci Res 1991; 28: 254–260.

31.

Kunis

Baruch

Rosenzweig

Kertser

Miller

Berkutzki

. IFN-gamma-dependent activation of the brain's choroid plexus for CNS immune surveillance and repair. Brain 2013; 136(Pt 11): 3427–3440.

32.

Schwartz

Kipnis

Rivest

Prat

. How do immune cells support and shape the brain in health, disease, and aging? J Neurosci 2013; 33: 17587–17596.

33.

Aguzzi

Barres

Bennett

. Microglia: scapegoat, saboteur, or something else? Science 2013; 339: 156–161.

34.

Spite

Serhan

. Novel lipid mediators promote resolution of acute inflammation: impact of aspirin and statins. Circ Res 2010; 107: 1170–1184.

35.

Schilling

Besselmann

Muller

Strecker

Ringelstein

Kiefer

. Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice. Exp Neurol 2005; 196: 290–297.

36.

Denes

Vidyasagar

Feng

Narvainen

McColl

Kauppinen

. Proliferating resident microglia after focal cerebral ischaemia in mice. J Cereb Blood Flow Metab 2007; 27: 1941–1953.

37.

Palmer

Willhoite

Gage

. Vascular niche for adult hippocampal neurogenesis. J Comp Neurol 2000; 425: 479–494.

38.

Ming

Song

. Adult neurogenesis in the mammalian brain: significant answers and significant questions. Neuron 2011; 70: 687–702.

39.

Suh

Deng

Gage

. Signaling in adult neurogenesis. Annu Rev Cell Dev Biol 2009; 25: 253–275.

40.

Sanai

Tramontin

Quinones-Hinojosa

Barbaro

Gupta

Kunwar

. Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration. Nature 2004; 427: 740–744.

41.

Quinones-Hinojosa

Sanai

Gonzalez-Perez

Garcia-Verdugo

. The human brain subventricular zone: stem cells in this niche and its organization. Neurosur Clin N Am 2007; 18: 15–20, vii.

42.

Spalding

Bergmann

Alkass

Bernard

Salehpour

Huttner

. Dynamics of hippocampal neurogenesis in adult humans. Cell 2013; 153: 1219–1227.

43.

Ernst

Alkass

Bernard

Salehpour

Perl

Tisdale

. Neurogenesis in the striatum of the adult human brain. Cell 2014; 156: 1072–1083.

44.

Curtis

Kam

Nannmark

Anderson

Axell

Wikkelso

. Human neuroblasts migrate to the olfactory bulb via a lateral ventricular extension. Science 2007; 315: 1243–1249.

45.

Wang

Liu

Zhao

You

Wang

. Identification and characterization of neuroblasts in the subventricular zone and rostral migratory stream of the adult human brain. Cell Res 2011; 21: 1534–1550.

46.

Clarke

van der Kooy

. The adult mouse dentate gyrus contains populations of committed progenitor cells that are distinct from subependymal zone neural stem cells. Stem Cells 2011; 29: 1448–1458.

47.

Zhao

Teng

Summers

Jr Ming

Gage

. Distinct morphological stages of dentate granule neuron maturation in the adult mouse hippocampus. J Neurosci 2006; 26: 3–11.

48.

Kyritsis

Kizil

Zocher

Kroehne

Kaslin

Freudenreich

. Acute inflammation initiates the regenerative response in the adult zebrafish brain. Science 2012; 338: 1353–1356.

49.

Jakubs

Bonde

Iosif

Ekdahl

Kokaia

. Inflammation regulates functional integration of neurons born in adult brain. J Neurosci 2008; 28: 12477–12488.

50.

Morrens

Van Den Broeck

Kempermann

. Glial cells in adult neurogenesis. Glia 2012; 60: 159–174.

51.

Ekdahl

Claasen

Bonde

Kokaia

Lindvall

. Inflammation is detrimental for neurogenesis in adult brain. Proc Natl Acad Sci USA 2003; 100: 13632–13637.

52.

Vallieres

Campbell

Gage

Sawchenko

. Reduced hippocampal neurogenesis in adult transgenic mice with chronic astrocytic production of interleukin-6. J Neurosci 2002; 22: 486–492.

53.

Ben-Hur

Ben-Menachem

Furer

Einstein

Mizrachi-Kol

Grigoriadis

. Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol Cell Neurosci 2003; 24: 623–631.

54.

Wong

Goldshmit

Turnley

. Interferon-gamma but not TNF alpha promotes neuronal differentiation and neurite outgrowth of murine adult neural stem cells. Exp Neurol 2004; 187: 171–177.

55.

Bachstetter

Morganti

Jernberg

Schlunk

Mitchell

Brewster

. Fractalkine and CX 3 CR1 regulate hippocampal neurogenesis in adult and aged rats. Neurobiol Aging 2011; 32: 2030–2044.

56.

Packer

Stasiv

Benraiss

Chmielnicki

Grinberg

Westphal

. Nitric oxide negatively regulates mammalian adult neurogenesis. Proc Natl Acad Sci USA 2003; 100: 9566–9571.

57.

Pluchino

Zanotti

Rossi

Brambilla

Ottoboni

Salani

. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature 2005; 436: 266–271.

58.

Bye

Turnley

Morganti-Kossmann

. Inflammatory regulators of redirected neural migration in the injured brain. Neurosignals 2012; 20: 132–146.

59.

Erlandsson

Lin

Morshead

. Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury. Exp Neurol 2011; 230: 48–57.

60.

Ziv

Ron

Butovsky

Landa

Sudai

Greenberg

. Immune cells contribute to the maintenance of neurogenesis and spatial learning abilities in adulthood. Nat Neurosci 2006; 9: 268–275.

61.

Iosif

Ahlenius

Ekdahl

Darsalia

Thored

Jovinge

. Suppression of stroke-induced progenitor proliferation in adult subventricular zone by tumor necrosis factor receptor 1. J Cereb Blood Flow Metab 2008; 28: 1574–1587.

62.

Iosif

Ekdahl

Ahlenius

Pronk

Bonde

Kokaia

. Tumor necrosis factor receptor 1 is a negative regulator of progenitor proliferation in adult hippocampal neurogenesis. J Neurosci 2006; 26: 9703–9712.

63.

Ziv

Avidan

Pluchino

Martino

Schwartz

. Synergy between immune cells and adult neural stem/progenitor cells promotes functional recovery from spinal cord injury. Proc Natl Acad Sci USA 2006; 103: 13174–13179.

64.

Monje

Toda

Palmer

. Inflammatory blockade restores adult hippocampal neurogenesis. Science 2003; 302: 1760–1765.

65.

Bonde

Ekdahl

Lindvall

. Long-term neuronal replacement in adult rat hippocampus after status epilepticus despite chronic inflammation. Eur J Neurosci 2006; 23: 965–974.

66.

Aarum

Sandberg

Haeberlein

Persson

. Migration and differentiation of neural precursor cells can be directed by microglia. Proc Natl Acad Sci USA 2003; 100: 15983–15988.

67.

Walton

Sutter

Laywell

Levkoff

Kearns

Marshall

2nd . Microglia instruct subventricular zone neurogenesis. Glia 2006; 54: 815–825.

68.

Gebara

Sultan

Kocher-Braissant

Toni

. Adult hippocampal neurogenesis inversely correlates with microglia in conditions of voluntary running and aging. Front Neurosci 2013; 7: 145.

69.

Ekdahl

Kokaia

Lindvall

. Brain inflammation and adult neurogenesis: the dual role of microglia. Neuroscience 2009; 158: 1021–1029.

70.

Lichtenwalner

Parent

. Adult neurogenesis and the ischemic forebrain. J Cereb Blood Flow Metab 2006; 26: 1–20.

71.

Liu

Solway

Messing

Sharp

. Increased neurogenesis in the dentate gyrus after transient global ischemia in gerbils. J Neurosci 1998; 18: 7768–7778.

72.

Tsai

Yang

Wang

. Intermittent hypoxia after transient focal ischemia induces hippocampal neurogenesis and c-Fos expression and reverses spatial memory deficits in rats. PloS One 2011; 6: e24001.

73.

Arvidsson

Collin

Kirik

Kokaia

Lindvall

. Neuronal replacement from endogenous precursors in the adult brain after stroke. Nat Med 2002; 8: 963–970.

74.

Tonchev

. Brain ischemia, neurogenesis, and neurotrophic receptor expression in primates. Arch Ital Biol 2011; 149: 225–231.

75.

Tonchev

Yamashima

Zhao

Okano

. Proliferation of neural and neuronal progenitors after global brain ischemia in young adult macaque monkeys. Mol Cell Neurosci 2003; 23: 292–301.

76.

Takagi

Nozaki

Takahashi

Yodoi

Ishikawa

Hashimoto

. Proliferation of neuronal precursor cells in the dentate gyrus is accelerated after transient forebrain ischemia in mice. Brain Res 1999; 831: 283–287.

77.

Tureyen

Vemuganti

Sailor

Bowen

Dempsey

. Transient focal cerebral ischemia-induced neurogenesis in the dentate gyrus of the adult mouse. J Neurosurg 2004; 101: 799–805.

78.

Jin

Minami

Lan

Mao

Batteur

Simon

. Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci USA 2001; 98: 4710–4715.

79.

Kee

Preston

Wojtowicz

. Enhanced neurogenesis after transient global ischemia in the dentate gyrus of the rat. Exp Brain Res 2001; 136: 313–320.

80.

Yagita

Kitagawa

Ohtsuki

Takasawa

Miyata

Okano

. Neurogenesis by progenitor cells in the ischemic adult rat hippocampus. Stroke 2001; 32: 1890–1896.

81.

Takasawa

Kitagawa

Yagita

Sasaki

Tanaka

Matsushita

. Increased proliferation of neural progenitor cells but reduced survival of newborn cells in the contralateral hippocampus after focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2002; 22: 299–307.

82.

Choi

Lee

Sung

Jeong

Choi

Park

. Regional differences in enhanced neurogenesis in the dentate gyrus of adult rats after transient forebrain ischemia. Mol Cells 2003; 16: 232–238.

83.

Tanaka

Yamashiro

Mochizuki

Cho

Onodera

Mizuno

. Neurogenesis after transient global ischemia in the adult hippocampus visualized by improved retroviral vector. Stroke 2004; 35: 1454–1459.

84.

Liu

Chopp

Zhang

. MicroRNAs in cerebral ischemia-induced neurogenesis. J Neuropathol Exp Neurol 2013; 72: 718–722.

85.

Parent

Vexler

Gong

Derugin

Ferriero

. Rat forebrain neurogenesis and striatal neuron replacement after focal stroke. Ann Neurol 2002; 52: 802–813.

86.

Zhang

Chopp

Gregg

Toh

Roberts

Letourneau

. Patterns and dynamics of subventricular zone neuroblast migration in the ischemic striatum of the adult mouse. J Cereb Blood Flow Metab 2009; 29: 1240–1250.

87.

Jin

Sun

Xie

Peel

Mao

Batteur

. Directed migration of neuronal precursors into the ischemic cerebral cortex and striatum. Mol Cell Neurosci 2003; 24: 171–189.

88.

Mohamad

Genetta

Wei

. Sublethal transient global ischemia stimulates migration of neuroblasts and neurogenesis in mice. Transl Stroke Res 2010; 1: 184–196.

89.

Thored

Wood

Arvidsson

Cammenga

Kokaia

Lindvall

. Long-term neuroblast migration along blood vessels in an area with transient angiogenesis and increased vascularization after stroke. Stroke 2007; 38: 3032–3039.

90.

Liu

You

Nie

Wei

. Brain injury does not alter the intrinsic differentiation potential of adult neuroblasts. J Neurosci 2009; 29: 5075–5087.

91.

Lampl

Boaz

Gilad

Lorberboym

Dabby

Rapoport

. Minocycline treatment in acute stroke: an open-label, evaluator-blinded study. Neurology 2007; 69: 1404–1410.

92.

Edaravone Acute Infarction Study G. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters. Cerebrovasc Dis 2003; 15: 222–229.

93.

Enlimomab Acute Stroke Trial I. Use of anti-ICAM-1 therapy in ischemic stroke: results of the Enlimomab Acute Stroke Trial. Neurology 2001; 57: 1428–1434.

94.

Bath

Iddenden

Bath

Orgogozo

. Tirilazad International Steering C. Tirilazad for acute ischaemic stroke. Cochrane Database Syst Rev 2001, CD002087.

95.

Krams

Lees

Hacke

Grieve

Orgogozo

Ford

. Acute Stroke Therapy by Inhibition of Neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke. Stroke 2003; 34: 2543–2548.

96.

Shuaib

Lees

Lyden

Grotta

Davalos

Davis

. NXY-059 for the treatment of acute ischemic stroke. N Eng J Med 2007; 357: 562–571.

97.

Liu

Xia

Wang

Song

Yang

Yan

. Efficacy and safety of ginsenoside-Rd for acute ischaemic stroke: a randomized, double-blind, placebo-controlled, phase II multicenter trial. Eur J Neurol 2009; 16: 569–575.

98.

Norris

Hachinski

. High dose steroid treatment in cerebral infarction. Br Med J 1986; 292: 21–23.

99.

Emsley

Smith

Georgiou

Vail

Hopkins

Rothwell

. A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients. J Neurol Neurosurg Psychiatry 2005; 76: 1366–1372.

100.

Lyden

Shuaib

Lees

Davalos

Davis

Diener

. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the CHANT Trial. Stroke 2007; 38: 2262–2269.

101.

Pettigrew

Kasner

Albers

Gorman

Grotta

Sherman

. Safety and tolerability of arundic acid in acute ischemic stroke. J Neurol Sci 2006; 251: 50–56.

102.

Salter-Cid

Linnik

Wang

Paisansathan

Pelligrino

. Vascular adhesion protein-1 plays an important role in postischemic inflammation and neuropathology in diabetic, estrogen-treated ovariectomized female rats subjected to transient forebrain ischemia. J Pharmacol Exp Ther 2006; 317: 19–29.

103.

Hodges

Sowinski

Virley

Nelson

Kershaw

Watson

. Functional reconstruction of the hippocampus: fetal versus conditionally immortal neuroepithelial stem cell grafts. Novartis Found Symp 2000; 231: 53–65, discussion 65-9.

104.

Hodges

Veizovic

Bray

French

Rashid

Chadwick

. Conditionally immortal neuroepithelial stem cell grafts reverse age-associated memory impairments in rats. Neuroscience 2000; 101: 945–955.

105.

Brannen

Kim

Sugaya

. Human neural stem cells improve cognitive function of aged brain. Neuroreport 2001; 12: 1127–1132.

106.

Park

Eve

Sanberg

Musso

3rd Bachstetter

Wolfson

. Increased neuronal proliferation in the dentate gyrus of aged rats following neural stem cell implantation. Stem Cells Dev 2010; 19: 175–180.

107.

Roy

Benraiss

Wang

Fraser

Goodman

Couldwell

. Promoter-targeted selection and isolation of neural progenitor cells from the adult human ventricular zone. J Neurosci Res 2000; 59: 321–331.

108.

Hallbergson

Gnatenco

Peterson

. Neurogenesis and brain injury: managing a renewable resource for repair. J Clin Investig 2003; 112: 1128–1133.

109.

Nakashiba

Cushman

Pelkey

Renaudineau

Buhl

McHugh

. Young dentate granule cells mediate pattern separation, whereas old granule cells facilitate pattern completion. Cell 2012; 149: 188–201.

110.

Yang

Hsu

Ming

Song

. A critical period for enhanced synaptic plasticity in newly generated neurons of the adult brain. Neuron 2007; 54: 559–566.

111.

Mongiat

Esposito

Lombardi

Schinder

. Reliable activation of immature neurons in the adult hippocampus. PloS One 2009; 4: e5320.

112.

Schmidt-Hieber

Jonas

Bischofberger

. Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus. Nature 2004; 429: 184–187.

113.

Barone

Arvin

White

Miller

Webb

Willette

. Tumor necrosis factor-alpha. A mediator of focal ischemic brain injury. Stroke 1997; 28: 1233–1244.

114.

Lambertsen

Clausen

Babcock

Gregersen

Fenger

Nielsen

. Microglia protect neurons against ischemia by synthesis of tumor necrosis factor. J Neurosci 2009; 29: 1319–1330.

115.

Clausen

Lambertsen

Babcock

Holm

Dagnaes-Hansen

Finsen

. Interleukin-1beta and tumor necrosis factor-alpha are expressed by different subsets of microglia and macrophages after ischemic stroke in mice. J Neuroinflammation 2008; 5: 46.

116.

Ohtaki

Yin

Nakamachi

Dohi

Kudo

Makino

. Expression of tumor necrosis factor alpha in nerve fibers and oligodendrocytes after transient focal ischemia in mice. Neurosci Lett 2004; 368: 162–166.

117.

Wang

Yue

Barone

White

Gagnon

Feuerstein

. Concomitant cortical expression of TNF-alpha and IL-1 beta mRNAs follows early response gene expression in transient focal ischemia. Mol Chem Neuropathol 1994; 23: 103–114.

118.

Boutin

LeFeuvre

Horai

Asano

Iwakura

Rothwell

. Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci 2001; 21: 5528–5534.

119.

Berti

Williams

Moffett

Hale

Velarde

Elliott

. Quantitative real-time RT-PCR analysis of inflammatory gene expression associated with ischemia-reperfusion brain injury. J Cereb Blood Flow Metab 2002; 22: 1068–1079.

120.

Herrmann

Tarabin

Suzuki

Attigah

Coserea

Schneider

. Regulation of body temperature and neuroprotection by endogenous interleukin-6 in cerebral ischemia. J Cereb Blood Flow Metab 2003; 23: 406–415.

121.

Loddick

Turnbull

Rothwell

. Cerebral interleukin-6 is neuroprotective during permanent focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 1998; 18: 176–179.

122.

Yamashita

Sawamoto

Suzuki

Adachi

Kawase

. Blockade of interleukin-6 signaling aggravates ischemic cerebral damage in mice: possible involvement of Stat3 activation in the protection of neurons. J Neurochem 2005; 94: 459–468.

123.

Mukaida

Matsumoto

Yokoi

Harada

Matsushima

. Inhibition of neutrophil-mediated acute inflammation injury by an antibody against interleukin-8 (IL-8). Inflamm Res 1998; 47(Suppl 3): S151–S157.

124.

Kostulas

Pelidou

Kivisakk

Kostulas

Link

. Increased IL-1beta, IL-8, and IL-17 mRNA expression in blood mononuclear cells observed in a prospective ischemic stroke study. Stroke 1999; 30: 2174–2179.

125.

Konoeda

Shichita

Yoshida

Sugiyama

Muto

Hasegawa

. Therapeutic effect of IL-12/23 and their signaling pathway blockade on brain ischemia model. Biochem Biophys Res Commun 2010; 402: 500–506.

126.

Yilmaz

Arumugam

Stokes

Granger

. Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation 2006; 113: 2105–2112.

127.

Yasuda

Shimoda

Uno

Tateishi

Furuya

Tsuchihashi

. Temporal and sequential changes of glial cells and cytokine expression during neuronal degeneration after transient global ischemia in rats. J Neuroinflammation 2011; 8: 70.

128.

Iadecola

Zhang

Casey

Nagayama

Ross

. Delayed reduction of ischemic brain injury and neurological deficits in mice lacking the inducible nitric oxide synthase gene. J Neurosci 1997; 17: 9157–9164.

129.

Iadecola

Zhang

Casey

Clark

Ross

. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996; 27: 1373–1380.

130.

Gidday

Gasche

Copin

Shah

Perez

Shapiro

. Leukocyte-derived matrix metalloproteinase-9 mediates blood-brain barrier breakdown and is proinflammatory after transient focal cerebral ischemia. Am J Physiology Heart Circ Physiol 2005; 289: H558–H568.

131.

Wang

Guo

Hossain

Fazio

Zeynalov

Janigro

. Bone marrowderived cells are the major source of MMP-9 contributing to blood-brain barrier dysfunction and infarct formation after ischemic stroke in mice. Brain Res 2009; 1294: 183–192.

132.

Montaner

Alvarez-Sabin

Molina

Angles

Abilleira

Arenillas

. Matrix metalloproteinase expression after human cardioembolic stroke: temporal profile and relation to neurological impairment. Stroke 2001; 32: 1759–1766.

133.

Shimakura

Kamanaka

Ikeda

Kondo

Suzuki

Umemura

. Neutrophil elastase inhibition reduces cerebral ischemic damage in the middle cerebral artery occlusion. Brain Res 2000; 858: 55–60.

134.

Stowe

Adair-Kirk

Gonzales

Perez

Shah

Park

. Neutrophil elastase and neurovascular injury following focal stroke and reperfusion. Neurobiol Dis 2009; 35: 82–90.

135.

de Bilbao

Arsenijevic

Moll

Garcia-Gabay

Vallet

Langhans

. in vivo over-expression of interleukin-10 increases resistance to focal brain ischemia in mice. J Neurochem 2009; 110: 12–22.

136.

Grilli

Barbieri

Basudev

Brusa

Casati

Lozza

. Interleukin-10 modulates neuronal threshold of vulnerability to ischaemic damage. Eur J Neurosci 2000; 12: 2265–2272.

137.

Ooboshi

Ibayashi

Shichita

Kumai

Takada

Ago

. Postischemic gene transfer of interleukin-10 protects against both focal and global brain ischemia. Circulation 2005; 111: 913–919.

138.

Quirie

Demougeot

Bertrand

Mossiat

Garnier

Marie

. Effect of stroke on arginase expression and localization in the rat brain. Eur J Neurosci 2013; 37: 1193–1202.

139.

Henrich-Noack

Prehn

Krieglstein

. TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Doseresponse relationship and potential neuroprotective mechanisms. Stroke 1996; 27: 1609–1614, discussion 1615.

140.

Ruocco

Nicole

Docagne

Ali

Chazalviel

Komesli

. A transforming growth factor-beta antagonist unmasks the neuroprotective role of this endogenous cytokine in excitotoxic and ischemic brain injury. J Cereb Blood Flow Metab 1999; 19: 1345–1353.

141.

Zhu

Yang

Ahlemeyer

Pang

Che

Culmsee

. Transforming growth factor-beta 1 increases bad phosphorylation and protects neurons against damage. J Neurosci 2002; 22: 3898–3909.

142.

Lehrmann

Kiefer

Finsen

Diemer

Zimmer

Hartung

. Cytokines in cerebral ischemia: expression of transforming growth factor beta-1 (TGF-beta 1) mRNA in the postischemic adult rat hippocampus. Exp Neurol 1995; 131: 114–123.

143.

Wang

Yue

White

Barone

Feuerstein

. Transforming growth factor-beta 1 exhibits delayed gene expression following focal cerebral ischemia. Brain Res Bull 1995; 36: 607–609.

144.

Peters

Back

Lindauer

Busch

Megow

Dreier

. Increased formation of reactive oxygen species after permanent and reversible middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab 1998; 18: 196–205.

145.

Piantadosi

Zhang

. Mitochondrial generation of reactive oxygen species after brain ischemia in the rat. Stroke 1996; 27: 327–331, discussion 332.

146.

Kunz

Anrather

Zhou

Orio

Iadecola

. Cyclooxygenase-2 does not contribute to postischemic production of reactive oxygen species. J Cereb Blood Flow Metab 2007; 27: 545–551.

147.

Dirnagl

Lindauer

Them

Schreiber

Pfister

Koedel

. Global cerebral ischemia in the rat: online monitoring of oxygen free radical production using chemiluminescence in vivo. J Cereb Blood Flow Metabol 1995; 15: 929–940.

148.

Takizawa

Aratani

Fukuyama

Maeda

Hirabayashi

Koyama

. Deficiency of myeloperoxidase increases infarct volume and nitrotyrosine formation in mouse brain. J Cereb Blood Flow Metab 2002; 22: 50–54.

149.

Breckwoldt

Chen

Stangenberg

Aikawa

Rodriguez

Qiu

. Tracking the inflammatory response in stroke in vivo by sensing the enzyme myeloperoxidase. Proc Natl Acad Sci USA 2008; 105: 18584–18589.

150.

van Breda

van der Worp

van Gemert

Algra

Kappelle

van Gijn

. PAIS: paracetamol (acetaminophen) in stroke; protocol for a randomized, double blind clinical trial [ISCRTN 74418480]. BMC Cardiovasc Disord 2005; 5: 24.